Biotechnology Lartruvo (olaratumab), in combination with doxorubicin, has been recommended by the medicines cost-effectiveness watchdog for England and Wales for use as an option for advanced soft tissue sarcoma in adults who have not had any previous systemic chemotherapy for advanced soft tissue sarcoma and cannot have curative treatment with surgery or their disease does not respond to radiotherapy. 12 June 2017